Use of adenovirus type-5 vectored vaccines: a cautionary tale

Affiliations

¹ Bridge HIV, San Francisco Department of Public Health, San Francisco, CA 94102, USA; Department of Medicine and Department of Epidemiology, University of California, San Francisco, CA, USA. Electronic address: susan.buchbinder@sfdph.org.
² Fred Hutchinson Cancer Research Institute, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, University of Washington, Seattle, WA, USA.
³ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Comment

Susan P Buchbinder et al. Lancet. 2020.

. 2020 Oct 31;396(10260):e68-e69.

doi: 10.1016/S0140-6736(20)32156-5. Epub 2020 Oct 19.

¹ Bridge HIV, San Francisco Department of Public Health, San Francisco, CA 94102, USA; Department of Medicine and Department of Epidemiology, University of California, San Francisco, CA, USA. Electronic address: susan.buchbinder@sfdph.org.
² Fred Hutchinson Cancer Research Institute, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Vaccine and Infectious Disease Division, University of Washington, Seattle, WA, USA.
³ Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Comment in

COVID-19 vaccination and HIV-1 acquisition.
Logunov DY, Livermore DM, Ornelles DA, Bayer W, Marques E, Czerkinsky C, Dolzhikova IV, Ertl HC. Logunov DY, et al. Lancet. 2022 Apr 9;399(10333):e34-e35. doi: 10.1016/S0140-6736(22)00332-4. Lancet. 2022. PMID: 35397866 Free PMC article. No abstract available.

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Zhu FC, et al. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22. Lancet. 2020. PMID: 32450106 Free PMC article. Clinical Trial.

1. Zhu FC, Li YH, Guan XH. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. - PMC - PubMed
1. Buchbinder SP, Mehrotra DV, Duerr A. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. - PMC - PubMed
1. Gray GE, Allen M, Moodie Z. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11:507–515. - PMC - PubMed
1. Moodie Z, Metch B, Bekker LG. Continued follow-up of Phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men. PLoS One. 2015;10 - PMC - PubMed
1. Duerr A, Huang Y, Buchbinder S. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) J Infect Dis. 2012;206:258–266. - PMC - PubMed